BioMark Diagnostics, Inc. · CSE:BUX
BioMark Diagnostics — Investor Presentation (July 2022)
33 slides from BioMark Diagnostics's investor presentation, July 2022

Slide 1: A Next Generation Company Powered by Metabolomics and Artificial Intelligence
A NEXT GENERATION COMPANY POWERED BY METABOLOMICS AND ARTIFICIAL INTELLIGENCE

Slide 2: Our Mission / Who We Are
Our Mission Who We Are • Developer of a metabolomics liquid biopsy- Provide better cancer detection, based platform leveraging machine learning monitoring and screening solutions for with advanced near-to-market diagnostic hard to detect cancers technologies. • Multiple IP’s in detection and quantit

Slide 3: Metabolomics
METABOLOMICS me·tab·o·lo·mics | \ mə-ˈta-bə-ˌlō-miks : a form of clinical chemistry that uses advanced analytical techniques to measure the complete collection of “small molecules” found in a given biological sample that offers rapid, inexpensive, comprehensive, quantitative characterization of…

Slide 4: The Advantages of Metabolomics
THE ADVANTAGES OF METABOLOMICS There are differences in the genomes of cancer cells and tissues in different cancer patients. This heterogeneity of cancer cells impacts the accuracy and applicability of many diagnostic markers for genes and proteins. These markers for genes and proteins may be effec

Slide 5: Cancer Is a Metabolic Disease
CANCER IS A METABOLIC DISEASE 5 Source: Hallmarks of Cancer - Hanahan D, Wienberg RA (2011) Cell, 144:646-674.

Slide 6: Early Detection Is Critical to Save Lives
EARLY DETECTION IS CRITICAL TO SAVE LIVES 6

Slide 7: Global Cancer Biomarkers Market
GLOBAL CANCER BIOMARKERS MARKET Forecast to 2028 Growth Drivers : Market growth is driven by the increasing use of cancer biomarkers in drug discovery and development, increasing research on cancer biomarkers, technological advancements, and the increasing global incidence of cancer. Rising technolo

Slide 8: Liquid Biopsy Platform & Product Pipeline
LIQUID BIOPSY PLATFORM & PRODUCT PIPELINE Completed development of 2 metabolomic assays – Platform Play Planning Development Validation Regulatory Approval Market Customize assay; Collect more clinical data and Lung Cancer Metabolic Fingerprint Assay build LDT for early lung cancer detection and scr

Slide 9: Projects in Process
PROJECTS IN PROCESS Metabolomic Fingerprint Assay Development Early Lung cancer - 1200 retrospective studies following 260 trial at IUCPQ for early detection of lung cancer. Expanded the sample size to include more subtypes, other lung diseases, other morbidities and different cancers. – Sponsored r

Slide 10: Patent Family in Use in Different Jurisdictions
PATENT FAMILY IN USE IN DIFFERENT JURISDICTIONS SSAT1 use for Early lung cancer GBM therapeutic response to treatment detection target in lung and brain METHOD OF DETECTING LUNG cancers CANCER GLIOBLASTOMA TUMOR GROWTH INHIBITON BY SAT1 METHOD OF DETECTING KNOCKDOWN A METHOD FOR ASSAYING THE CANCER

Slide 11: Lung Cancer Metabolic Fingerprint Assay
Lung Cancer Metabolic Fingerprint Assay 11

Slide 12: Lung Cancer – The Big Picture
LUNG CANCER – THE BIG PICTURE Lung cancer has been the most Most common common cancer in the world for several decades and accounts for 1 in 5 of all cancer deaths. Worldwide, three people die from lung Deadly cancer every minute Because of the lower specificity of LDCT, 96 % of all nodules discover

Slide 13: Lung Cancer – Stage Shifting Impact
LUNG CANCER – STAGE SHIFTING IMPACT • The lung cancer five-year survival rate (18.6 percent) is lower than many other leading cancer sites, such as colorectal (64.5 percent), breast (89.6 percent) and prostate (98.2 percent). • The five-year survival rate for lung cancer is 56 percent for cases dete

Slide 14: Lung Cancer Screening Highlights
LUNG CANCER SCREENING HIGHLIGHTS Large Undeserved Market Target - Lung Cancer Screening for identified high risk groups to complement LDCT Scan Estimated Population Size : 16 million in USA 1.4 million in Canada 0.4 million in Québec only Current Uptake 5% in USA – No organized lung cancer screening

Slide 15: Strong Tailwinds
STRONG TAILWINDS Active VA screening programs seeking better Current lung cancer Limited access to LDCT screening technology for at screening rates in US is especially in rural risk veterans across the estimated at 5% communities country. Program being funded under NCI Cancer Moonshot has been reign

Slide 16: Established Accepted Test (LDT) Coupled with Robust Technology Backbone
ESTABLISHED ACCEPTED TEST (LDT) COUPLED WITH ROBUST TECHNOLOGY BACKBONE The lung cancer metabolites are easily measured using quantitative mass spectrometry (MS) methods with standard instruments used in diagnostic clinical laboratories across Canada and USA. • the amount of blood required (<20 µL),

Slide 17: Targeted Metabolomics Lung Cancer Trials
Targeted Metabolomics Lung Cancer Trials Data Summary Total Subjects: 257 Normal: 60 Lung Cancer: 197 (emphasis on Stages 1 and 2) Metabolomics Analysis: Human plasma samples* were analyzed using custom developed assay for several putative lung cancer biomarkers. *Samples and data obtained from IUCP

Slide 18: Strong Performance for Early-Stage Detection
STRONG PERFORMANCE FOR EARLY-STAGE DETECTION Logistic regression based optimal model for stages I + II Logistic regression based on optimal model for stages I + II NSCLC detection: metabolites only NSCLC detection: metabolites plus smoking history 18

Slide 19: Strong Performance for Early-Stage Detection
STRONG PERFORMANCE FOR EARLY-STAGE DETECTION P E R F O R M AN C E O F L O G I S T I C R E G R E S S I O N P E R F O R M AN C E O F L O G I S T I C R E G R E S S I O N MODEL A MODEL B AUC SENSITIVITY SPECIFICITY AUC SENSITIVITY SPECIFICITY TRAINING/ 0.974 (0.965 ~ 0.937 (0.920 ~ 0.922 (0.895 ~ TRAINI

Slide 20: BioMark's Advantage Over LDCT Scan for Lung Cancer Screening
BIOMARK’S ADVANTAGE OVER LDCT SCAN FOR LUNG CANCER SCREENING LDCT BIOMARK’S LIQUID BIOPSY 73.4% (SPECIFICITY) 96.1% (SPECIFICITY) % EARLY STAGE DETECTION 93.8% (SENSITIVITY) 94.4% (SENSITIVITY) FALSE POSITIVE RATES HIGH MUCH LOWER COST >$1000 <$400 RADIATION IMPACT OVER 18% COMPLICATIONS NONE False

Slide 21: Impending Catalyst – Short Term Canada
IMPENDING CATALYST – SHORT TERM CANADA Lung Cancer Panel Assay Development Timeline Stage I/II Lung Cancer Present Discovery Screening data to Study Open R&D Internal Validation CQDM regulatory Publication Facilities in Qc Assay V&V (4000 samples) agencies 2020 2021 2022 2023 Partnership with Clinic

Slide 22: Lung Cancer Screening Validation Outline - Ongoing
LUNG CANCER SCREENING VALIDATION OUTLINE - ONGOING DISCOVERY COHORT VALIDATION COHORT Screening project T1 year T2 year T3 year Patient selection (PanCan risk model); n=3000 Genetic Clinical follow-up profile No lesion IUCPQ Biobank Polygenic score Low risk lesion EGFR Status 4,000 lung lesion patie

Slide 23: Options for Growth
OPTIONS FOR GROWTH Lung Cancer - Panel Assay • ISO -15189 accredited lab services • Establish beachhead in Quebec with IUCPQ and expand services across Canada • Discuss collaboration with VHA (Veterans Health Authority) • Build / Acquire Labs or Partner in US for assay validation with licensing opti

Slide 24: Catalysts in Q2 and Q3 2022
CATALYSTS IN Q2 AND Q3 2022 Complete 1200 retrospective lung cancer analysis and data readout – Medteq and Sparks Grant funded study Conduct V&V studies for lab accreditation based on 1200 lung cancer samples Present at ASMS in June 2022 to demonstrate the clinical validation and utility of BioMark’

Slide 25: Value Proposition – Actionable Diagnostic Test
VALUE PROPOSITION- ACTIONABLE DIAGNOSTIC TEST Our technology solution – offers • Early diagnosis and screening – Application in screening for aggressive and hard to detect cancers such as lung and brain cancers. • Effective monitoring tool to assess treatment efficacy earlier so as to improve tailor

Slide 26: Management Team – Rashid A. Bux
MANAGEMENT TEAM Rashid A.Bux - Founder & CEO Rashid Ahmed - Founder and CEO of BioMark Diagnostics Inc, started his journey into the medical sector as a science student at Nairobi University. He holds a Master of Business Administration from the University of Western Ontario and a Bachelor of Scienc

Slide 27: Management Team – Dr. Jean-Francois Haince
MANAGEMENT TEAM Dr. Jean-Francois Haince - CSO and GM Dr. Haince holds a PhD in Cellular and Molecular Biology from the Faculty of Medicine at Université Laval. He cumulates over 15 years of experience in cancer research and authored over 20 peer-reviewed scientific publications. During his term at

Slide 28: Management Team – Guoyu Huang
MANAGEMENT TEAM Guoyu Huang – CFO Guoyu (Gina) Huang, the CFO of BioMark Diagnostics Inc. and the President of BioMark Diagnostic Solutions Inc, has been a core management team member of BioMark since 2013. With the ability and experience to examine and understand business needs and deliver comprehe

Slide 29: BioMark Corporate Structure
BIOMARK CORPORATE STRUCTURE 29

Slide 30: Current Facilities in North America & Global Network
CURRENT FACILITIES IN NORTH AMERICA & GOBAL NETWORK Clinical Laboratory Québec, Canada University of Brescia Astrazeneca Global China Italy UK Bangladesh Head Office Vancouver, Canada Pfizer Canada France Mount Sinaï New York, USA Brazil 30

Slide 31: BioMark Cap Table Summary
BIOMARK CAP TABLE SUMMARY • Trading Symbols: CSE: BUX / OTCMKTS: BMKDF / FSE: 20B • Common Shares Issued and Outstanding: 83,286,229 • Warrants (@ $0.45): 6,177,579 • Options (@ $0.15 - $0.30): 4,135,000 • Insiders ownership: 65% • Capital Raised (to-date): CAD $ 14.5 m 31

Slide 32: What We Offer
WHAT WE OFFER • Disciplined scale • Growth oriented • Solid Platform for hard to detect and treat cancers -Near commercial ready assays • Strong sponsored research – peer reviewed/validation • IP portfolio • Defined route to revenue. Strategy and approach is defensible • Clinical partners • Executio

Slide 33: Contact Details
Contact Details Rashid Bux Founder and CEO rahmed@biomarkdiagnostics.com Mobile: 1- 604-836-6950 www.biomarkdiagnostics.com A NEXT GENERATION COMPANY POWERED BY METABOLOMICS AND 33 ARTIFICIAL INTELLIGENCE
Source: Internet Archive copy of biomarkdiagnostics.com
More decks from BioMark Diagnostics, Inc.
Investor Presentation (September 2025)23 slides · September 2025
Investor Presentation (April 2023)42 slides · April 2023
Investor Presentation (May 2021)26 slides · May 2021
Investor Presentation (June 2019)32 slides · June 2019
Investor Presentation (June 2016)23 slides · June 2016
Investor Presentation (July 2015)25 slides · July 2015